Bavarian Nordic A/S buy blaugold
Start price
21.06.23
/
50%
€27.33
Target price
21.06.24
-
Performance (%)
1.24%
End price
25.06.23
€27.67
Summary
This prediction ended on 25.06.23 with a price of €27.67. With a performance of 1.24%, the BUY prediction by blaugold for Bavarian Nordic A/S closed with a slight gain. blaugold has 50% into this predictionBavarian Nordic (symbol: BAVA) is a biotechnology company that specializes in developing innovative vaccines for serious diseases such as cancer and infectious diseases like Ebola and COVID-19. The company has a broad portfolio of vaccines that are under development and has collaboration agreements with various pharmaceutical companies and government agencies. Bavarian Nordic's flagship product is its cancer vaccine known as PROSTVAC, which is currently undergoing clinical trials for the treatment of prostate cancer. The company is listed on the NASDAQ Copenhagen stock exchange and has a market capitalization of approximately $925 million as of May 2021.
Performance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Bavarian Nordic A/S | 7.939% | 7.939% | -1.095% |
| iShares Core DAX® | -0.543% | 1.491% | 13.638% |
| iShares Nasdaq 100 | -2.696% | -1.235% | 31.879% |
| iShares Nikkei 225® | -2.863% | 2.491% | 12.078% |
| iShares S&P 500 | -1.105% | 0.013% | 26.888% |
Comments by blaugold for this prediction
In the thread Bavarian Nordic A/S diskutieren
Buy Bavarian Nordic A/S